Clinical Trial Update: SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A combined regimen including SHR-1210 with albumin-bound paclitaxel and epirubicin is being investigated as neoadjuvant therapy for triple-negative breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Epirubicin (epirubicin)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Triple-negative Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN